Tufik Assad, MD
Pulmonary Disease · Boston, MANPI 1093941890
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,504 of the $132,015 with a category attached, or 65.5%. Biofire Diagnostics, LLC accounts for 68.0% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2019 at $55,816 and has fallen 98.5% since, to $837 in 2025. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $458.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biofire Diagnostics, LLC$90K
- Biomerieux Inc$25K
- Veran Medical Technologies, Inc.$10K
- Novartis$2K
- Medtronic$1K
- GSK$647
- plus $3K from 39 others
What the payments were for
- Consulting fees$10,6008%
- Speaking & faculty fees$86,50466%
- Travel & lodging$28,95022%
- Food & beverage$5,8364%
- Education$1260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Film Array System$33,044
- BioFire FilmArray$30,450
- FILMARRAY PNEUMONIA PANEL (PNEUMO)$24,999
- Film Array$22,890
- Spin$9,722
- XOLAIR$1,444
- ILLUMISITE$1,035
- FilmArray Pneumonia Panel plus (Pneumoplus)$124
- SPiN Thoracic Navigation System, 120V, 60Hz$119
How this compares
$132,015 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 113 | $1,408,916 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 409 | $310,175 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 25 | $95,833 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 92 | $69,914 |
| Pirfenidone | 12 | $57,260 |
| NucalaMepolizumab | 12 | $45,147 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $36,702 |
| Spiriva RespimatTiotropium Bromide | 57 | $35,167 |
| EliquisApixaban | 42 | $25,249 |
| SymbicortBudesonide/Formoterol Fumarate | 85 | $25,117 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $18,390 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $16,101 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 70 | $11,732 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $11,662 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 206 | $5,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $396 | $1,460,185200 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $647 | $426,311559 claims |
| Grifols USA, LLCGamunex-C | $54 | $95,83325 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $419 | $95,031177 claims |
| PfizerEliquis | $41 | $25,24942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
- Kelsey SackBoston$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.